Form 4 for TGTX TG THERAPEUTICS, INC.
Accepted 2023-03-14 00:00:00 ET · period of report 2023-03-12 · accession 0001104659-23-032337 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-14 | 2023-03-12 | TGTX | WEISS MICHAEL S | CEO, Pres, Dir | A - Grant | $0.00 | +985.0K | 11.97M | +9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | COMMON STOCK | 2023-03-12 | A | A | 985,000 | $0.00 | 11,973,021 | D | — | — | (F1) Reflects a grant of restricted shares, which will vest and become non-forfeitable based on the Company's total shareholder return relative to the Nasdaq Biotechnology Index over a one-year to five-year period, provided that the Reporting Person remains an employee, director and/or consultant of the Company through each vesting date. (F2) Includes shares of restricted Common Stock, which vest over various time periods. |